Programmed death-1: Therapeutic success after more than 100 years of cancer immunotherapy

Alexander Dömling, Tad A Holak

Research output: Contribution to journalEditorialAcademicpeer-review

59 Citations (Scopus)

Abstract

No other cancer therapy target class caused more excitement than the programmed death-1 (PD-1) pathway related. Antibodies against PD-1 and PD-1 ligands represent a therapeutic breakthrough and are the first examples of broadly efficacious and durable cancer immunotherapies. Cancer for the first time seems to have transformed from an often incurable to a "clinically manageable" disease.

Original languageEnglish
Pages (from-to)2286-2288
Number of pages3
JournalAngewandte Chemie - International Edition
Volume53
Issue number9
DOIs
Publication statusPublished - 24-Feb-2014

Keywords

  • antibodies
  • cancer immunotherapy
  • immune checkpoint
  • programmed death 1
  • protein-protein interactions
  • MELANOMA
  • TRIAL
  • ANTIBODIES
  • ANTI-PD-1
  • SAFETY

Fingerprint

Dive into the research topics of 'Programmed death-1: Therapeutic success after more than 100 years of cancer immunotherapy'. Together they form a unique fingerprint.

Cite this